Interleukin-6 Treatment Induces Beta-cell Apoptosis Via STAT-3-mediated Nitric Oxide Production
Overview
Affiliations
Background: Type 2 diabetes is characterized by progressive beta-cell failure and apoptosis is probably the main form of beta-cell death in this disease. It was reported that circulating levels of interleukin-6 are elevated in type 2 diabetic patients, but whether this is involved in the pathogenesis of type 2 diabetes is still debated. In this study, we examined whether interleukin-6 can induce beta-cell damage in vitro and elucidated its mechanisms.
Methods: To examine the effect of interleukin-6 on beta cells, glucose-stimulated insulin secretion (GSIS) by enzyme immunoassay (EIA) method and cell apoptosis by propidium iodide and annexin-V staining were measured in a rat beta-cell line (INS-1 or INS-832/13) after treatment with interleukin-6. The expression of apoptosis-related molecules was measured using western blotting and nitric oxide (NO) production was measured using Griess assay. AG490 and N-monomethyl-L-arginine were used to inhibit Janus kinase-mediated signal transducers and activators of transcription signalling and NO production, respectively.
Results: Exposure (48 h) of INS-1 cells to 20 ng/mL interleukin-6 significantly decreased GSIS as well as cell viability. We found that sub-G1/G0 population was increased as compared with untreated cells and expression of cleaved caspase-3, cleaved poly(ADP-ribose) polymerase, phosphorylated p38 mitogen-activated protein kinase and phosphorylated nuclear factor-κB was increased in interleukin-6-treated INS-1 cells. Interleukin-6 increased the amount of early apoptotic cells; this increase was blocked by AG490 or N-monomethyl-L-arginine treatment. Moreover, NO production, which is known to induce apoptosis, was increased by interleukin-6 treatment but abrogated in AG490-treated cells.
Conclusion: Our results show that exposure to interleukin-6 for 48 h can induce beta-cell death, in part via signal transducers and activators of transcription-3-mediated NO production.
Villaca C, Mastracci T Compr Physiol. 2024; 14(2):5371-5387.
PMID: 39109973 PMC: 11425433. DOI: 10.1002/cphy.c230008.
Gojani E, Wang B, Li D, Kovalchuk O, Kovalchuk I Genes (Basel). 2024; 15(2).
PMID: 38397173 PMC: 10888174. DOI: 10.3390/genes15020183.
Biondi G, Marrano N, Borrelli A, Rella M, Palma G, Calderoni I Int J Mol Sci. 2022; 23(10).
PMID: 35628332 PMC: 9143684. DOI: 10.3390/ijms23105522.
Mooranian A, Foster T, Ionescu C, Walker D, Jones M, Wagle S Pharmaceutics. 2021; 13(8).
PMID: 34452145 PMC: 8398365. DOI: 10.3390/pharmaceutics13081184.
Basmaeil Y, Subayyil A, Abumaree M, Khatlani T Front Cell Dev Biol. 2021; 9:650125.
PMID: 34235143 PMC: 8255990. DOI: 10.3389/fcell.2021.650125.